Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Mar
10
Today In Oncology
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
AI-Backed Liquid Biopsies Identify Liver Diseases
Peter WT Pisters Honored With Top Award From Society of Surgical Oncology
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo